An MIT-led research team has developed a drug capsule that could be used to deliver oral doses of insulin, potentially replacing the injections that people with type 2 diabetes have to give themselves every day.
Now, researchers have discovered a way to stop mosquitoes biting — by using human ‘diet’ drugs to trick them into feeling full. The scientists suggest that the drugs could one day be used to control the spread of diseases.
Capsule that releases insulin in the stomach could replace injections for patients with type 1 diabetes.
The U.S. Food and Drug Administration today approved Cablivi (caplacizumab-yhdp) injection, the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive therapy, for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening disorder that causes blood clotting.
A way to diagnose a severe neurological disorder can’t be patented as it covers a law of nature, a U.S. appeals court ruled Wednesday in a closely watched case that sought to clarify the patenting for medical diagnostic tests and instead has resulted in calls for Congress to step in.
DNA sequences called retrotransposons can copy themselves and reintegrate at new sites in the genome, causing damage. It now seems that inhibiting this process can prevent age-related health decline in mice.
The wonder-material graphene could hold the key to unlocking the next generation of advanced, early stage lung cancer diagnosis.
The only CAR-T cell therapy available for NHS patients in England and Wales for two distinct blood cancers – will be available on the NHS in England and Wales to eligible adults who did not respond to two or more previous treatments with DLBCL, with funding from the Cancer Drugs Fund (CDF).
Pfizer receives positive CHMP opinion for Vizimpro® (dacomitinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR-activating mutations
Vizimprowas approved by the U.S. Food and Drug Administration (FDA) in 2018 for the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. It was also recently approved in Japan for EGFR gene mutation-positive, inoperable or recurrent NSCLC.
Researchers around the world interested in unravelling the mechanisms of complex human disorders, such as Alzheimer’s disease, could soon have access to cloned monkeys with genomes that have been edited to display these conditions in China.